← All People

James Sacchettini

Sacchettini, James
James Sacchettini
Professor of Biochemistry and Biophysics and of Chemistry; Wolfe-Welch Chair in Science
ILSB / Room 2138A
Undergraduate Education
B.A St. Louis University (1980)
Graduate Education
Ph.D. Washington University, St. Louis (1987)
Postdoc. Washington University, St. Louis (1987-89)
Professor. Albert Einstein College of Medicine
Joined Texas A&M in 1996

Crystallography / Drug Design

My lab uses X-ray crystallography to better understand the relationship between proteins and ligands. Tiny differences in the structure of a molecule can radically change the interaction between a protein and ligand and we are only begining to understand how many factors play a role in this interaction. By manipulating the individual components of a compound it is possible to create a chemical that binds to the protein better than the natural substrate, and prevent the natural reaction from occurring. This is the basis for rational drug design. Our efforts have lead us to collaborations with other labs and scientists in many disciplines as our approach to directed compound design has applications not only in basic research but also in pesticide development, health research and clinical research.

Recent Publications

  1. Ganley, JG, Carr, G, Ioerger, TR, Sacchettini, JC, Clardy, J, Derbyshire, ER et al.. Discovery of Antimicrobial Lipodepsipeptides Produced by a Serratia sp. within Mosquito Microbiomes. Chembiochem. 2018; :.
    doi: 10.1002/cbic.201800124. PubMed PMID:29700993. .

  2. Tiwari, D, Park, SW, Essawy, MM, Dawadi, S, Mason, A, Nandakumar, M et al.. Targeting protein biotinylation enhances tuberculosis chemotherapy. Sci Transl Med. 2018;10 (438):.
    doi: 10.1126/scitranslmed.aal1803. PubMed PMID:29695454. .

  3. Korkegian, A, O'Malley, T, Xia, Y, Zhou, Y, Carter, DS, Sunde, B et al.. The 7-phenyl benzoxaborole series is active against Mycobacterium tuberculosis. Tuberculosis (Edinb). 2018;108 :96-98.
    doi: 10.1016/j.tube.2017.11.003. PubMed PMID:29523334. PubMed Central PMC5854369.

  4. Murugesan, D, Ray, PC, Bayliss, T, Prosser, GA, Harrison, JR, Green, K et al.. 2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure-Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS Infect Dis. 2018;4 (6):954-969.
    doi: 10.1021/acsinfecdis.7b00275. PubMed PMID:29522317. PubMed Central PMC5996347.

  5. Carey, AF, Rock, JM, Krieger, IV, Chase, MR, Fernandez-Suarez, M, Gagneux, S et al.. TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathog. 2018;14 (3):e1006939.
    doi: 10.1371/journal.ppat.1006939. PubMed PMID:29505613. PubMed Central PMC5854444.

  6. Negri, A, Javidnia, P, Mu, R, Zhang, X, Vendome, J, Gold, B et al.. Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis. ACS Infect Dis. 2018;4 (5):771-787.
    doi: 10.1021/acsinfecdis.7b00111. PubMed PMID:29465985. PubMed Central PMC5952258.

  7. Lehmann, J, Cheng, TY, Aggarwal, A, Park, AS, Zeiler, E, Raju, RM et al.. An Antibacterial β-Lactone Kills Mycobacterium tuberculosis by Disrupting Mycolic Acid Biosynthesis. Angew. Chem. Int. Ed. Engl. 2018;57 (1):348-353.
    doi: 10.1002/anie.201709365. PubMed PMID:29067779. .

  8. Chandrasekera, NS, Berube, BJ, Shetye, G, Chettiar, S, O'Malley, T, Manning, A et al.. Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB. ACS Infect Dis. 2017;3 (12):898-916.
    doi: 10.1021/acsinfecdis.7b00112. PubMed PMID:29035551. PubMed Central PMC5727484.

  9. Yang, K, Chang, JY, Cui, Z, Li, X, Meng, R, Duan, L et al.. Structural insights into species-specific features of the ribosome from the human pathogen Mycobacterium tuberculosis. Nucleic Acids Res. 2017;45 (18):10884-10894.
    doi: 10.1093/nar/gkx785. PubMed PMID:28977617. PubMed Central PMC5737476.

  10. Taira, J, Morita, K, Kawashima, S, Umei, T, Baba, H, Maruoka, T et al.. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. J. Antibiot. 2017;70 (11):1057-1064.
    doi: 10.1038/ja.2017.106. PubMed PMID:28951604. .

Search PubMed